Literature DB >> 9836469

Chemotherapy for ovarian cancer--trials, controversies and funding.

R E Hawkins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836469      PMCID: PMC2063227          DOI: 10.1038/bjc.1998.698

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  2 in total

1.  Chemotherapy for ovarian cancer--a consensus statement on standard practice.

Authors:  M Adams; A H Calvert; J Carmichael; P I Clark; R E Coleman; H M Earl; C J Gallagher; T S Ganesan; M E Gore; J D Graham; P G Harper; G C Jayson; S B Kaye; J A Ledermann; R J Osborne; T J Perren; C J Poole; J A Radford; G J Rustin; M L Slevin; J F Smyth; H Thomas; P M Wilkinson
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

2.  First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.

Authors:  J Sandercock; M K Parmar; V Torri
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.